Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Tien D, Su K, Reynolds Z, Li Y, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Li JZ, Siedner MJ, Barczak AK, Lemieux JE, Perelson AS.
Phan T, et al. Among authors: uddin r.
bioRxiv [Preprint]. 2024 Sep 16:2024.09.13.613000. doi: 10.1101/2024.09.13.613000.
bioRxiv. 2024.
PMID: 39345409
Free PMC article.
Preprint.